We are sincerely grateful to Michael, Anne and Bryan for their time, leadership and valuable contributions to IKCC. Their work has helped strengthen international collaboration and advance the patient voice in kidney cancer advocacy.

During the 2026 IKCC Global Kidney Cancer Summit in Prague, they took part in the Looking Back, Looking Forward session, sharing their perspectives on the progress made in kidney cancer care and advocacy, as well as their thoughts on the future of the kidney cancer community.

We would like to recognise and thank three outgoing members of the IKCC Board: Michael Jewett, Anne Wilson and Bryan Lewis, for their dedication and commitment to kidney cancer advocacy.

The session will feature: 🔹 Dr Brian Shuch 🔹 Dr David Braun 🔹 Genetic counsellor Lindsey Byrne, MS, LGC A Community Social will follow the Town Hall, offering an opportunity for patients, caregivers and others to continue the conversation.

🧬 Genetics & Kidney Cancer Town Hall What does genetics mean for people living with kidney cancer and their families? Join KidneyCAN on 28 October to learn about inherited kidney cancer, genetic testing and emerging research.

If you have been diagnosed with kidney cancer or care for someone who has, we invite you to complete the survey. It takes approximately 15 minutes, and all responses remain confidential. Previous participants are also welcome to take part again.

This year marks 10 years of the Global Patient Survey, giving us a decade of valuable insights to guide future advocacy, education and support programmes. Haven't taken part yet? There's still time to have your say! 🗣️

Every response helps us better understand the experiences of people living with kidney cancer and identify areas where care and support can be improved.

🎉 Over 1,000 patients and carers have already contributed to the IKCC Global Patient Survey 2026–2027! A big thank you to everyone who has taken the time to share their experiences. 💙

Their support helped bring together more than 50 patient advocates, healthcare professionals and kidney cancer experts from around the world for two days of knowledge-sharing, collaboration and discussion.

The success of the 2026 IKCC Global Kidney Cancer Summit would not have been possible without the support of our sponsors. We would like to extend our sincere thanks to Arcus, Exelixis and Pfizer for supporting this year's Summit in Prague.

Bringing global health perspectives into conversations with patient advocates is an important part of strengthening the kidney cancer community and ensuring that patient needs remain central to cancer policy and decision-making.

Dr Ilbawi also contributed to discussions on improving access to essential medicines and treatments, highlighting the importance of addressing inequalities in cancer care.